Placenta-Derived Therapeutics

摘要

Preeclampsia is a leading killer of pregnant women and a major contributor to maternal and foetal morbidity. Occurring in 3-8% of pregnant women worldwide, it is diagnosed by the new onset of high blood pressure, and either elevated protein in the urine or pulmonary edema, cerebral or visual symptoms, low platelets, or specific signs of kidney or liver dysfunction, beginning in the 20th week of pregnancy (1-3). Although most affected pregnancies deliver at or close to term with good outcomes, women with preeclampsia can be at an increased risk of life-threatening events, including stroke and grand mal seizures (eclampsia). There is also an increased incidence of placental insufficiency and foetal growth restriction. Due to these potentially adverse outcomes, a key aspect of routine prenatal care is monitoring for signs and symptoms of this disorder.